Advertiment
Hegmans JP, Veltman JD, Lambers ME, de Vries IJ, Figdor CG, Hendriks RW, Hoogsteden HC, Lambrecht BN, Aerts JG.
Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands.
RATIONALE: Earlier we have demonstrated that dendritic cell-based immunotherapy induced protective antitumor immunity with prolonged survival in mice. However, the clinical relevance is still questioned. We designed a clinical trial using chemotherapy followed by antigen-pulsed dendritic cell vaccination in mesothelioma patients OBJECTIVES: The aim of this study was to assess the safety and immunological response induced by the administration of tumor lysate-pulsed dendritic cells in mesothelioma patients. METHODS: Ten patients with malignant pleural mesothelioma received three vaccinations of clinical-grade autologous dendritic cells intradermally and intravenously at two-week intervals after chemotherapy. Each vaccine was composed of 50×10(6) mature dendritic cells pulsed with autologous tumor lysate and keyhole limpet hemocyanin (KLH) as surrogate marker. Delayed-type hypersensitivity activity to tumor antigens and KLH was assessed, both in vivo and in vitro. Peripheral blood mononuclear cells during the treatment were analyzed for immunological responses. MAIN RESULTS: Administration of dendritic cells pulsed with autologous tumor lysate in mesothelioma patients was safe with moderate fever as the only side effect. There were no grade 3 or 4 toxicities associated with the vaccines or any evidence of autoimmunity. Local accumulations of infiltrating T cells were found at the site of vaccination. The vaccinations induced distinct immunological responses to KLH, both in vitro and in vivo. Importantly, after three vaccinations, cytotoxic activity against autologous tumor cells was detected in a subgroup of patients. CONCLUSIONS: This study demonstrated that autologous tumor lysate-pulsed dendritic cell-based therapy is feasible, well-tolerated, and capable of inducing immunological response to tumor cells in mesothelioma patients. www.clinicaltrials.gov NCT00280982.
Related Search
figdor cg postdoctoral,
Leave a Reply
Suggested Posts
Potential New Treatment For Kidney Cancer By Specific Inhibition Of Autophagy Hegma s JP, Veltma JD, Lambers ME, de Vries IJ, Figdor CG, He driks RW, Hoogstede HC, Lambrecht BN, Aerts JG. Pulmo ary Medici e, Erasmus MC, Rotterdam, Netherla ds. RATIONALE: Earlier we have demo strated that de dritic cell-based immu otherapy i duced protective a titumor immu ity with prolo ged survival i mice. However, the cli ical releva ce is still questio ed. We desig ed a cli ical trial [...]. Posted February 18th, 2010 | 6:04 pm
Treatment Of Gynecologic Cancers Reduced From 5 Weeks To 3 Days Using New Radiation Therapy Hegma s JP, Veltma JD, Lambers ME, de Vries IJ, Figdor CG, He driks RW, Hoogstede HC, Lambrecht BN, Aerts JG. Pulmo ary Medici e, Erasmus MC, Rotterdam, Netherla ds. RATIONALE: Earlier we have demo strated that de dritic cell-based immu otherapy i duced protective a titumor immu ity with prolo ged survival i mice. However, the cli ical releva ce is still questio ed. We desig ed a cli ical trial [...]. Posted February 18th, 2010 | 6:04 pm
Joint Clinical Practice Guidelines On Hepatocellular Carcinoma Management To Be Published By EASL-EORTC Hegma s JP, Veltma JD, Lambers ME, de Vries IJ, Figdor CG, He driks RW, Hoogstede HC, Lambrecht BN, Aerts JG. Pulmo ary Medici e, Erasmus MC, Rotterdam, Netherla ds. RATIONALE: Earlier we have demo strated that de dritic cell-based immu otherapy i duced protective a titumor immu ity with prolo ged survival i mice. However, the cli ical releva ce is still questio ed. We desig ed a cli ical trial [...]. Posted February 18th, 2010 | 6:04 pm
Potential Strategy Aims To Stimulate The Immune System To Defeat Cancers Hegma s JP, Veltma JD, Lambers ME, de Vries IJ, Figdor CG, He driks RW, Hoogstede HC, Lambrecht BN, Aerts JG. Pulmo ary Medici e, Erasmus MC, Rotterdam, Netherla ds. RATIONALE: Earlier we have demo strated that de dritic cell-based immu otherapy i duced protective a titumor immu ity with prolo ged survival i mice. However, the cli ical releva ce is still questio ed. We desig ed a cli ical trial [...]. Posted February 18th, 2010 | 6:04 pm
Roche medicine Avastin receives EU approval for the treatment of women with newly diagnosed, advanced ovarian cancer Hegma s JP, Veltma JD, Lambers ME, de Vries IJ, Figdor CG, He driks RW, Hoogstede HC, Lambrecht BN, Aerts JG. Pulmo ary Medici e, Erasmus MC, Rotterdam, Netherla ds. RATIONALE: Earlier we have demo strated that de dritic cell-based immu otherapy i duced protective a titumor immu ity with prolo ged survival i mice. However, the cli ical releva ce is still questio ed. We desig ed a cli ical trial [...]. Posted February 18th, 2010 | 6:04 pm